Voya Investment Management LLC purchased a new stake in shares of Insys Therapeutics, Inc. (NASDAQ:INSY) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 11,751 shares of the specialty pharmaceutical company’s stock, valued at approximately $149,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Insys Therapeutics during the second quarter valued at about $138,000. American International Group Inc. increased its position in shares of Insys Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of Insys Therapeutics by 213.2% during the second quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 8,940 shares during the period. UBS Asset Management Americas Inc. purchased a new position in shares of Insys Therapeutics during the first quarter valued at about $172,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of Insys Therapeutics during the second quarter valued at about $240,000. Institutional investors own 25.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Voya Investment Management LLC Takes Position in Insys Therapeutics, Inc. (INSY)” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/23/voya-investment-management-llc-takes-position-in-insys-therapeutics-inc-insy.html.

Insys Therapeutics, Inc. (INSY) opened at $5.20 on Thursday. Insys Therapeutics, Inc. has a 52 week low of $4.10 and a 52 week high of $15.02.

Several equities analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research report on Sunday, November 12th. Jefferies Group LLC reduced their price target on shares of Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 3rd. Royal Bank Of Canada set a $8.00 price objective on shares of Insys Therapeutics and gave the stock a “buy” rating in a report on Friday, October 27th. Zacks Investment Research cut shares of Insys Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Finally, BidaskClub upgraded shares of Insys Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 26th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $9.38.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Want to see what other hedge funds are holding INSY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insys Therapeutics, Inc. (NASDAQ:INSY).

Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.